Bial Medical Colloquia: Epilepsy series (Webinar 2)
20 Jul 2021
About the event
This two-part-webinar series will discuss how an ever-improving understanding of the mechanism of action of antiseizure medicines can help healthcare professionals to decide how to deploy different combination therapy; in order to optimise efficacy and tolerability of antiseizure drugs in patients with refractory epilepsy.
Founded in 1924, BIAL’s mission is to discover, develop and provide new therapeutic solutions within the area of Health. Today, BIAL is an innovative international pharmaceutical company with products available in more than 55 countries. The company is committed to making a contribution to improve human health and quality of life for people from all over the world.
Strongly committed to therapeutic innovation, and consistently investing more than 20% of its annual revenue in Research and Development (R&D), BIAL has established an ambitious R&D programme. Key focus areas for the Group are the neurosciences and cardiovascular. The Bial team currently consists of 900 workers. We bring together our knowledge, experience, imagination and dedication to achieve a concrete goal: providing high quality medicines. 79% of our workers have higher education qualifications, 7% of which are PhDs.
